Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer

Clinical Immunology

Volumn 138, Issue 1, 2011, Pages 23-32

  Sun, Zhao ^a   Shi, Liang ^b   Zhang, Huagang ^b   Shao, Yi ^b   Wang, Yu ^b   Lin, Yi ^c   Li, Xiaolin ^c   Bai, Chunmei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; EAAL; IFN

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 10;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; COLON CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXPANDED ACTIVATED AUTOLOGOUS LYMPHOCYTE THERAPY; FEMALE; HUMAN; IMMUNOMODULATION; INJECTION SITE CHILL; INJECTION SITE DIARRHEA; INJECTION SITE DIZZINESS; INJECTION SITE FEVER; INJECTION SITE REACTION; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLEURA METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BLOOD TRANSFUSION, AUTOLOGOUS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 78651356883     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.08.012     Document Type: Article

References (38)

1. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003, 3(9):666-676.
2. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J. Med. 1985, 313(23):1485-1492.
3. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Vetto J.T., Seipp C.A., Simpson C. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233(4770):1318-1321.
4. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J. Med. 1987, 316(15):889-897.
5. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., Aebersold P., Leitman S., Linehan W.M., Seipp C.A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 1993, 85(8):622-632.
6. Law T.M., Motzer R.J., Mazumdar M., Sell K.W., Walther P.J., O'Connell M., Khan A., Vlamis V., Vogelzang N.J., Bajorin D.F. Phase-III randomized trial of interleukin-2 with or without lymphokine-activated killer-cells in the treatment of patients with advanced renal-cell carcinoma. Cancer 1995, 76(5):824-832.
7. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 1994, 86(15):1159-1166.
8. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse human lymphoma model to evaluate cytokine-induced killer-cells with potent antitumor cell-activity. J. Exp. Med. 1991, 174(1):139-149.
9. Linn Y.C., Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk. Lymphoma 2003, 44(9):1457-1462.
10. Weng D.S., Zhou J., Zhou Q.M., Zhao M., Wang Q.J., Huang L.X., Li Y.Q., Chen S.P., Wu P.H., Xia J.C. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother. 2008, 31(1):63-71.
11. Sekine T., Shiraiwa H., Yamazaki T., Tobisu K., Kakizoe T. A feasible method for expansion of peripheral-blood lymphocytes by culture with immobilized anti-CD3 monoclonal-antibody and interleukin-2 for use in adoptive immunotherapy of cancer-patients. Biomed. Pharmacother. 1993, 47(2-3):73-78.
12. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356(9232):802-807.
13. Montes M., Rufer N., Appay V., Reynard S., Pittet M.J., Speiser D.E., Guillaume P., Cerottini J.C., Romero P., Leyvraz S. Optimum in vitro expansion of human antigen-specific CD8(+) T cells for adoptive transfer therapy. Clin. Exp. Immunol. 2005, 142(2):292-302.
14. Whiteside T.L., Sung M.W., Nagashima S., Chikamatsu K., Okada K., Vujanovic N.L. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Clin. Cancer Res. 1998, 4(5):1135-1145.
15. Arca M.J., Krauss J.C., Aruga A., Cameron M.J., Chang A.E. Concurrent induction of CD4(+) and CD8(+) T cells during tumor growth with antitumor reactivity in adoptive immunotherapy. J. Immunother. 1997, 20(2):138-145.
16. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13(2):95-109.
17. Emtage P.C., Clarke D., Gonzalo-Daganzo R., Junghans R.P. Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J. Immunother. 2003, 26(2):97-106.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. Feb 2 2000, 92(3):205-216.
19. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer Jan 2009, 45(2):228-247.
20. Zou W.P. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5(4):263-274.
21. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3(11):991-998.
22. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 2004, 22(6):1136-1151.
23. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001, 2(4):293-299.
24. Brittenden J., Heys S.D., Ross J., Eremin O. Natural killer cells and cancer. Cancer 1996, 77(7):1226-1243.
25. Terabe M., Berzofsky J.A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 2004, 16(2):157-162.
26. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., Rosenberg S.A., Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174(5):2591-2601.
27. Schabowsky R.H., Madireddi S., Sharma R., Yolcu E.S., Shirwan H. Targeting CD4(+)CD25(+)Foxp3(+) regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs 2007, 8(12):1002-1008.
28. Thistlethwaite F.C., Elkord E., Griffiths R.W., Burt D.J., Shablak A.M., Campbell J.D., Gilham D.E., Austin E.B., Stern P.L., Hawkins R.E. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol. Immunother. 2008, 57(5):623-634.
29. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 1997, 15:297-322.
30. Halverson D.C., Schwartz G.N., Carter C., Gress R.E., Fowler D.H. In vitro generation of allospecific human CD8(+) T cells of Tc1 and Tc2 phenotype. Blood 1997, 90(5):2089-2096.
31. Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994, 370(6491):650-652.
32. Carter L.L., Dutton R.W. Relative perforin-mediated and fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 1995, 155(3):1028-1031.
33. Lum L.G., LeFever A.V., Treisman J.S., Garlie N.K., Hanson J.P. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells - phase I clinical trial. J. Immunother. 2001, 24(5):408-419.
34. Caras I., Grigorescu A., Stavaru C., Radu D.L., Mogos I., Szegli G., Salageanu A. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol. Immunother. 2004, 53(12):1146-1152.
35. De Vita F., Orditura M., Galizia G., Romano C., Roscigno A., Lieto E., Catalano G. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000, 117(2):365-373.
36. De Vita F., Orditura M., Galizia G., Romano C., Infusino S., Auriemma A., Lieto E., Catalano G. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 1999, 86(10):1936-1943.
37. Antonia S., Mule J.J., Weber J.S. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 2004, 16(2):130-136.
38. Yannelli J.R., Wroblewski J.A. On the road to a tumor cell vaccine: 20years of cellular immunotherapy. Vaccine 2004, 23(1):97-113.